Vaccinations in CLL: implications for COVID-19.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed, 21 citations in OpenAlex.

1. Ibrutinib enhances the bias of T cell responses towards staphylococcal superantigens sustaining inflammation in chronic lymphocytic leukaemia.Frontiers in immunology · 2025
   Article
2. Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia.Blood advances · 2023
   Article
3. Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study.PLoS medicine · 2023
   Observational
4. High risk of infection in 'real-world' patients receiving ibrutinib, idelalisib or venetoclax for mature B-cell leukaemia/lymphoma.European journal of haematology · 2023
   Article
5. COVID-19 Vaccination Response and Its Practical Application in Patients With Chronic Lymphocytic Leukemia.HemaSphere · 2023
   Review
6. Patients with Chronic Lymphocytic Leukemia Have a Very High Risk of Ineffective Response to the BNT162b2 Vaccine.Vaccines · 2022
   Article
7. Early Cellular and Humoral Responses Developed in Oncohematological Patients after Vaccination with One Dose against COVID-19.Journal of clinical medicine · 2022
   Article
8. The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia.British journal of haematology · 2022
   Article
9. A Systematic Review on the Prevention and Control of Opportunistic Infections in Patients With Chronic Lymphocytic Leukemia Complicated by Richter's Transformation.Cureus · 2022
   Review
10. Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.Haematologica · 2022
    Article
11. Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations.Therapeutic advances in hematology · 2022
    Review
12. Serologic response to mRNA COVID-19 vaccination in lymphoma patients.American journal of hematology · 2021
    Observational
13. Hairy cell leukemia and COVID-19 adaptation of treatment guidelines.Leukemia · 2021
    Review
14. Vaccination against COVID-19: a challenge in CLL.Blood · 2021
    Article
15. Impact of COVID-19 in patients with lymphoid malignancies.World journal of virology · 2021
    Review
16. Venetoclax-Rituximab Treatment of Relapsed/Refractory CLL During the COVID-19 Pandemic: A Real-Life Experience in Selected Central-Southern Italian Regions.Mediterranean journal of hematology and infectious diseases · 2021
    Article

Corrections and comments

• Comment on
  Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.2021

Authors and funding

2 authors at 1 institution in 2 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as